id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-E-3650-0006,FDA,FDA-2017-E-3650,"Determination of Regulatory Review Period for Purposes of Patent
Extension; OCALIVA",Notice,Determinations,2018-12-04T05:00:00Z,2018,12,2018-12-04T05:00:00Z,2019-02-05T04:59:59Z,2018-12-04T14:17:27Z,2018-26288,0,0,0900006483939066
FDA-2017-E-3650-0005,FDA,FDA-2017-E-3650,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2018-11-20T05:00:00Z,2018,11,2018-11-20T05:00:00Z,,2018-11-20T13:23:38Z,,0,0,09000064838eb878
FDA-2017-E-3650-0004,FDA,FDA-2017-E-3650,Letter from  the U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2018-10-02T04:00:00Z,2018,10,2018-10-02T04:00:00Z,,2018-10-02T15:48:19Z,,0,0,090000648378c30d